enVVeno Medical Corp (NVNBW) Financial Statements (2025 and earlier)

Company Profile

Business Address 70 DOPPLER
IRVINE, CA 92618
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments38,94143,15348,37939,06742,94246,412
Cash and cash equivalent2,9371,75417,9152,3802,3143,620
Short-term investments36,00441,39930,46436,68740,62842,792
Other undisclosed current assets538581672469306511
Total current assets:39,47943,73449,05139,53643,24846,923
Noncurrent Assets
Operating lease, right-of-use asset9251,0071,0901,1761,2611,347
Property, plant and equipment142182218252289334
Other undisclosed noncurrent assets313131313131
Total noncurrent assets:1,0981,2201,3391,4591,5811,712
TOTAL ASSETS:40,57744,95450,39040,99544,82948,635
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,2911,7311,8721,3441,1431,033
Accounts payable7031,006894698604427
Accrued liabilities588725978646539606
Other undisclosed accounts payable and accrued liabilities      
Other undisclosed current liabilities370364357351344338
Total current liabilities:1,6612,0952,2291,6951,4871,371
Noncurrent Liabilities
Liabilities, other than long-term debt6097007918829731,064
Operating lease, liability6097007918829731,064
Total noncurrent liabilities:6097007918829731,064
Total liabilities:2,2702,7953,0202,5772,4602,435
Equity
Equity, attributable to parent38,30742,15947,37038,41842,36946,200
Additional paid in capital194,665194,014192,996178,402177,397176,236
Accumulated deficit(156,358)(151,855)(145,626)(139,984)(135,028)(130,036)
Total equity:38,30742,15947,37038,41842,36946,200
TOTAL LIABILITIES AND EQUITY:40,57744,95450,39040,99544,82948,635

Income Statement (P&L) ($ in thousands)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Revenues
(Realized Investment gains)
426425428379408676
Gross profit:426425428379408676
Operating expenses(4,954)(6,699)(6,170)(5,454)(5,503)(6,278)
Other undisclosed operating loss(426)(425)(428)(379)(408)(676)
Operating loss:(4,954)(6,699)(6,170)(5,454)(5,503)(6,278)
Nonoperating income451470528498511629
Net loss available to common stockholders, diluted:(4,503)(6,229)(5,642)(4,956)(4,992)(5,649)

Comprehensive Income ($ in thousands)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Net loss:(4,503)(6,229)(5,642)(4,956)(4,992)(5,649)
Comprehensive loss, net of tax, attributable to parent:(4,503)(6,229)(5,642)(4,956)(4,992)(5,649)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: